Author

S. Natarajan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5 Cell Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 4 Organism:mouse· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

J. Easton· 2 shared M. A. Dyer· 2 shared M. Pan· 2 shared P. Geeleher· 2 shared A. B. Muir· 1 shared A. C. Koong· 1 shared A. D. Fuller· 1 shared A. G. Patel· 1 shared

Activity by Year

2019-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Easton

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Autophagy contributes to homeostasis in esophageal epithelium where high autophagic vesicle content marks basal cells with limited proliferation and enhanced self-renewal potential

A. Klochkova, A. L. Karami, A. D. Fuller, L. R. Parham, S. R. Panchani, S. Natarajan, J. L. Jackson, A. Mu, Y. Tan, K. Q. Cai, A. Klein-Szanto, A. B. Muir, M.-P. Tetreault, K. E. Hamilton, K. A. Whelan

The paper investigates autophagy's role in esophageal homeostasis, finding that high autophagic vesicle content in basal cells correlates with limited proliferation and enhanced self-renewal.

bioRxiv · Sep 20, 2023 · PreprintPhysiology

14K Prolactin Derived 14-Mer Antiangiogenic Peptide Targets Bradykinin-/Nitric Oxide-cGMP-Dependent Angiogenesis

J. Lee, P. Kumar, S. Natarajan, S. H. Park, S. Majumder, L. Sundaresan, K. Muralidhar, J.-S. Choi, H. J. Lee, S. Chatterjee

This study identifies a novel 14-mer antiangiogenic peptide derived from prolactin that inhibits bradykinin- and eNOS-dependent angiogenesis, showing synergistic effects with Avastin in a colon cancer model.

bioRxiv · Aug 21, 2023Cancer Biology

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs.

R. H. Chapple, X. Liu, S. Natarajan, M. I. M. Alexander, Y. Kim, A. G. Patel, C. W. LaFlamme, M. Pan, W. C. Wright, H.-M. Lee, Y. Zhang, M. Lu, S. C. Koo, C. Long, J. Harper, , P. Geeleher

The paper compares mesenchymal-like gene expression programs in neuroblastoma preclinical models and patient tumors using single-cell RNA-seq and identifies chemotherapy-induced changes in PDX and GEMM.

bioRxiv · Apr 13, 2023Cancer Biology

Sex-biased Yap1 oncogene function

N. Abdelfattah, S. Natarajan, J. Maldonado, H. N. Tran, R. McMinimy, H. Borland, S.-h. Chen, F. Camargo, J. Olson, J. George, K. Yun

This study shows that Yap1, an oncogene, has sex-biased functions in medulloblastoma progression and immune suppression, with greater impact in males.

bioRxiv · Dec 21, 2022 · PreprintCancer Biology

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M. Pan, C. Wright, R. Chapple, A. Zubair, M. Sandhu, J. Batchelder, J. Low, K. Blankenship, L. Wang, B. Gordon, P. Archer, S. W. Brady, S. Natarajan, M. Pozsgai, J. Schuetz, , P. Geeleher

This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.

bioRxiv · Feb 25, 2021Cancer Biology

Drug and siRNA screens identify ROCK2 as a therapeutic target for ciliopathies.

A. V. R. Lake, C. E. L. Smith, S. Natarajan, B. Basu, S. K. Best, T. Stevenson, R. Trowbridge, S. N. Grellscheid, J. Bond, R. Foster, C. A. Johnson

The paper identifies ROCK2 as a therapeutic target for ciliopathies through drug and siRNA screens, showing ROCK2 inhibitors could treat cystic kidney disease.

bioRxiv · Nov 26, 2020Cell Biology

FLASH irradiation enhances the therapeutic index of abdominal radiotherapy for the treatment of ovarian cancer

K. Levy, S. Natarajan, J. Wang, S. Chow, J. T. Eggold, P. Loo, R. Manjappa, F. M. Lartey, E. Schüler, L. Skinner, M. Rafat, R. Ko, A. Kim, D. Al Rawi, R. von Eyben, , E. B. Rankin

This study shows FLASH irradiation reduces intestinal injury while maintaining ovarian cancer treatment efficacy in preclinical models.

bioRxiv · Dec 12, 2019 · PreprintCancer Biology